Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.
Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.
复制标题
DOI：
10.1177/0272989x17700624
复制
发表时间：
2018-04
期刊：
影响因子：
--
通讯作者：
Plevritis SK
中科院分区：
文献类型：
--
作者：
Mandelblatt JS;Near AM;Miglioretti DL;Munoz D;Sprague BL;Trentham-Dietz A;Gangnon R;Kurian AW;Weedon-Fekjaer H;Cronin KA;Plevritis SK
自2000年成立以来，癌症干预和监测网络（CISNET）乳腺癌模型一直在合作，使用具有全国代表性的共同输入参数核心，代表每个模型中乳腺癌控制的关键组成部分。使用共同的输入允许更大的能力，比较模型输出时，每个模型开始与不同的输入参数。使用公共输入还增强了对结果的推断，并基于变量模型结构、假设和输入值的使用方法提供了一系列合理的结果。每次分析都会更新常用输入数据，以确保它们反映有关乳腺癌的最新实践和知识。共同的核心参数包括人口出生率和死亡率;在没有筛查和治疗的情况下，特定年龄和群体乳腺癌发病率的时间比率;风险因素对发病趋势的影响;平片和数字乳腺X线摄影的传播;筛查测试性能特征;按年龄分列的筛查、间隔和临床检测到的肿瘤的分期或大小分布;按年龄和分期的ER/HER 2联合分布;按分期和分子亚型在没有筛查和治疗的情况下的生存率;年龄、分期和分子亚型特异性治疗;随时间推移的治疗传播和有效性;以及竞争性非乳腺癌死亡率。在本文中，我们总结了目前在CISNET乳腺癌模型中使用的常用输入值的方法和结果，注意到由于不可观察的现象和/或不可用的数据所做的假设，并强调了未来参数开发的计划。这些数据旨在提高乳腺CISNET模型的透明度。
Since their inception in 2000, the Cancer Intervention and Surveillance Network (CISNET) breast cancer models have collaborated to use a nationally representative core of common input parameters to represent key components of breast cancer control in each model. Employment of common inputs permits greater ability to compare model output than when each model begins with different input parameters. Use of common inputs also enhances inferences about the results, and provides a range of reasonable results based on variations model structure, assumptions, and methods of use of the input values. The common input data are updated for each analysis to ensure that they reflect the most current practice and knowledge about breast cancer. The common core of parameters includes population rates of births and deaths; age- and cohort-specific temporal rates of breast cancer incidence in the absence of screening and treatment; effects of risk factors on incidence trends; dissemination of plain film and digital mammography; screening test performance characteristics; stage or size distribution of screen-, interval-, and clinically- detected tumors by age; the joint distribution of ER/HER2 by age and stage; survival in the absence of screening and treatment by stage and molecular sub-type; age-, stage-, and molecular subtype-specific therapy; dissemination and effectiveness of therapies over time; and competing non-breast cancer mortality. In this paper we summarize the methods and results for the common input values presently used in the CISNET breast cancer models, note assumptions made because of unobservable phenomena and/or unavailable data, and highlight plans for development of future parameters. These data are intended to enhance the transparency of the breast CISNET models.